GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Topotecan capsules - HYCAMTIN

Read renal action and limits
Local official-label summarySource retrieved 2026-09-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

HYCAMTIN capsules

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Hycamtin capsules - product and source limitations

The primary label table includes 49 mL/min in the 30-49 band; section 8.6 also uses the words less than 49. At this boundary verify section 2.3 of the exact capsule label.

Before applying: Consult the exact cited section and other applicable sources before use.

Evidence for this qualification

Selected renal passages reviewed; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Topotecan capsules - HYCAMTIN

Choose a product and source Product label GlobalRPh RX passage All evidence
Product / population
Oral HYCAMTIN capsules; relapsed SCLC with prior response and >=45 days since first-line treatment
Renal measure
Cockcroft-Gault CrCl, mL/min, using ideal body weight
Source revision
September 2023
Retrieved
2026-09-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal dosing, restrictions and evidence limits

For labeled relapsed small cell lung cancer, usual oral dosing is 2.3 mg/m2/day for five consecutive days starting a 21-day cycle. Using Cockcroft-Gault with ideal body weight, reduce to 1.5 mg/m2/day at CrCl 30-49 mL/min, and 0.6 mg/m2/day below 30.

Round to the nearest 0.25 mg using the minimum number of 1-mg and 0.25-mg capsules; swallow whole. Blood-count eligibility, diarrhea-related holds and toxicity modifications remain separate requirements. The below-30 band is not an independently established dialysis schedule. Do not use the IV product's renal dose or cancer-indication schedule for these capsules.

Source revision: September 2023 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23b46f5-c276-47f5-8bbd-940680b3f579

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Topotecan capsules - HYCAMTIN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Oral HYCAMTIN capsules; relapsed SCLC with prior response and >=45 days since first-line treatment

Renal method: Cockcroft-Gault CrCl, mL/min, using ideal body weight
Retrieved: 2026-09-07

Read local renal resultOpen this source quick answerOpen original reference
Official product label

Hycamtin capsules - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Topotecan (Hycamtin), adult oral capsules for relapsed small cell lung cancer

Renal method: Cockcroft-Gault CrCl using ideal body weight, mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Hycamtin capsules - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Topotecan (Hycamtin), adult oral capsules for relapsed small cell lung cancer

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Hycamtin capsules - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Hycamtin capsules - product and source limitations

The primary label table includes 49 mL/min in the 30-49 band; section 8.6 also uses the words less than 49. At this boundary verify section 2.3 of the exact capsule label.

How to use this: The primary label table includes 49 mL/min in the 30-49 band; section 8.6 also uses the words less than 49. At this boundary verify section 2.3 of the exact capsule label.

Hycamtin capsules - labeled renal guidanceHycamtin capsules - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeTopotecan capsules - HYCAMTINHycamtin capsules - labeled renal guidanceHycamtin capsules - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23b46f5-c276-47f5-8bbd-940680b3f579

Exact product and population

Oral HYCAMTIN capsules; relapsed SCLC with prior response and >=45 days since first-line treatment

RDM38-SCOPE-topotecan-hycamtin-capsules · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Topotecan capsules - HYCAMTIN

Open original reference

Open / share this exact local source

DailyMed / Sandoz · Oral HYCAMTIN capsules; relapsed SCLC with prior response and >=45 days since first-line treatment

Renal method: Cockcroft-Gault CrCl, mL/min, using ideal body weight
Source date: September 2023
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For labeled relapsed small cell lung cancer, usual oral dosing is 2.3 mg/m2/day for five consecutive days starting a 21-day cycle. Using Cockcroft-Gault with ideal body weight, reduce to 1.5 mg/m2/day at CrCl 30-49 mL/min, and 0.6 mg/m2/day below 30.

Round to the nearest 0.25 mg using the minimum number of 1-mg and 0.25-mg capsules; swallow whole. Blood-count eligibility, diarrhea-related holds and toxicity modifications remain separate requirements. The below-30 band is not an independently established dialysis schedule. Do not use the IV product's renal dose or cancer-indication schedule for these capsules.

RDM38-official-topotecan-hycamtin-capsules-dc66160907-C1 · Source locator: Sections 1, 2.1, 2.2 and 2.3

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23b46f5-c276-47f5-8bbd-940680b3f579
Retrieved
2026-09-07
Exact label title
Topotecan capsules - HYCAMTIN
DailyMed Set ID
b23b46f5-c276-47f5-8bbd-940680b3f579
Labeler
Sandoz
Label revision
September 2023
Renal-function method
Cockcroft-Gault CrCl, mL/min, using ideal body weight
Source date/version
September 2023
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4970ee31a4af0f9de1457a2a870fcc944348de4981aeef6dbcae1927d0651e73
Official

Hycamtin capsules - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Topotecan (Hycamtin), adult oral capsules for relapsed small cell lung cancer

Renal method: Cockcroft-Gault CrCl using ideal body weight, mL/min
Source date: DailyMed SPL version 1, effective 2023-09-18; posted Oct 31, 2024
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.1, 2.3 and 8.6

Limits that apply to these rows

Use the oral dose-modification table. Verify blood-count recovery before the next cycle. IV topotecan uses different doses.

Adult renal dosing in this source
Cockcroft-Gault CrCl (mL/min), ideal body weightOral starting dose on days 1-5 of each 21-day cycle
30-491.5 mg/m2/day
<300.6 mg/m2/day
Read the retained text before reformatting

Use Cockcroft-Gault with ideal body weight. At CrCl 30-49 mL/min, give 1.5 mg/m2/day; below 30, give 0.6 mg/m2/day. Both are on days 1-5 of the 21-day oral cycle. Use the oral dose-modification table. Verify blood-count recovery before the next cycle. IV topotecan uses different doses.

RDM73-hycamtin-capsules-official-1 · Source locator: Renal guidance: 2.1, 2.3 and 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23b46f5-c276-47f5-8bbd-940680b3f579
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl using ideal body weight, mL/min
Source date/version
DailyMed SPL version 1, effective 2023-09-18; posted Oct 31, 2024
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
f5678fa0ff20fe8762bd49f0756d103f1f9ec746f2a0ac0dd143ee98601a1166
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Hycamtin capsules - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Topotecan (Hycamtin), adult oral capsules for relapsed small cell lung cancer

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The capsule mirror separates moderate and severe impairment and identifies the weight convention for CrCl.

RDM73-hycamtin-capsules-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/hycamtin-capsules-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
ef31310e2d191989b19ace66ac23ca8f322c65a97f00ce002056f36f02db7e2c

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23b46f5-c276-47f5-8bbd-940680b3f579
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
source summary
Local text SHA-256
8bc10efdaa4efe1d38b1a513b8b4ebdef1b6fc72d0c5291eef9b5ec1737fa5ad
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top